Pain

We know that pain is huge financial burden on the Irish Health Service and more needs to be done, both to improve the lives of people affected by chronic pain, and to work towards more effective management of the many different types of pain.

Pain is one of the most significant healthcare problems the world faces today. It impacts hundreds of millions of people across the world, profoundly affecting their quality of life and costing society countless billions of pounds in treatment along with lost productivity.

Pain can be challenging to live with but new treatments over the past 20 years have considerably improved the quality of life of people with pain management issues. Teva offers a comprehensive range of pain management solutions that help healthcare professionals to respond effectively to the individual requirements of each patient.

While prescription pain medications are an important component of pain management, the reality is these products are prone to abuse and misuse. We are commited to advancing responsible pain management that meets the needs of healthcare professionals and people affected by pain.

To learn more about Teva's medicines and their availability in Ireland, or to speak to a Medical Affairs professional from Teva please contact us.

Applying expertise, innovation and technology to improve health

Making progress on pain management options is urgently needed. We are developing a focused pipeline of new drugs and novel treatments to meet patient and societal needs in pain management.

Our global research and development group is developing a focused portfolio of solutions that looks across the spectrum of pain states, including chronic nociceptive pain, cancer pain, and chronic neuropathic pain.

Exploring socially responsible pain treatments

We are addressing some of the key challenges associated with opioid-based treatments. Our global research and development team are focusing on abuse deterrent formulations and developing treatment options using our proprietary CIMA technology which is based on a multi-layer gel-forming polymer coating that regulates drug release.

Abuse-deterrent treatments provide options for prescribers that may help deter or mitigate abuse while still preserving access to pain medications for the patients that need them most.

We are dedicated to supporting our patients and healthcare professionals

Our work with patients, and our experience in this therapy area, means we are well placed to invest in extensive research into potential cures and medicines to help improve pain management, to offer patients and healthcare professionals a wider choice of treatments.

Life Effects™ - patient support from Teva

Poor health impacts life in so many different ways—physically, mentally, emotionally, socially and financially, to name a few. Chronic illness can turn life upside down.

Through Teva’s Life Effects™ website patients and caregivers share their tips and real life experiences to help other patients navigate their new normal. 


Life Effects™ for patients

The only people who understand the patient experience is other patients

Read their stories

Life Effects™ for caregivers

Navigating the challenges and joys of caregiving

Learn from other caregivers

Medical Affairs

Teva’s Medical Affairs team is responsible for providing medical support to our company
(both branded and generics), and for interacting with external customers through medical
information and medical education.

The goal of Medical Affairs is to advance our medical knowledge in key therapeutic areas,
including neurological disorders, oncology, pain management and respiratory diseases.
The team supports patients and healthcare professionals by providing medical
information, scientific communications and educational activities.

Medical Affairs ensures that Irish healthcare professionals are well informed about the safety
and efficacy profile of Teva’s products to support the proper use of our medicines and devices.

Medical Affairs Contact Information

E-mail Telephone

Migraine

Read more

Respiratory

Read more

Oncology

Read more

Consumer Health

Read more

Central Nervous System

Read more
Date of preparation: April 2021
Reference: COB-IE-NP-00042